Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR) announced that data from its Phase 1 clinical program for CTI-1601, aimed at treating Friedreich's Ataxia, will be presented at the International Congress for Ataxia Research from November 1-4, 2022, in Dallas, Texas. Key presentations will cover safety, pharmacokinetics, and gene expression findings related to CTI-1601. Notably, Nancy M. Ruiz, MD will present important data on November 3 at 4:00 PM CT.

Positive

• Presentation of promising data from Phase 1 trials of CTI-1601 at a significant conference.
• Potential advancement in treatment options for Friedreich's Ataxia, a complex rare disease.

Negative

• None.

BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in three presentations at the upcoming International Congress for Ataxia Research. The conference will take place November 1 – 4, 2022, in Dallas, Texas.

Details on the presentations are shown below.

Title:		Safety and Pharmacokinetics of Single and 13 Day Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy for Friedreich’s Ataxia
Presentation Format:		Oral
Presenting Author:		Nancy M. Ruiz, MD, Chief Medical Officer, Larimar Therapeutics
Presentation Date and Time:		November 3, 2022, at 4:00 PM CT

Title:		Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Presentation Format:		Poster
Presenting Author:		David Bettoun, PhD, Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics
Poster Session Date and Time:		12:00 -1:00 PM CT on November 2 and 3, 2022

Title:		Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients
Presentation Format:		Poster
Presenting Author:		Matthew Baile, PhD, Senior Research Investigator, Larimar Therapeutics
Poster Session Date and Time:		12:00 -1:00 PM CT on November 2 and 3, 2022

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is the focus of Larimar Therapeutics?

Larimar Therapeutics specializes in developing treatments for complex rare diseases.

When and where will Larimar present data on CTI-1601?

Larimar will present data on CTI-1601 at the International Congress for Ataxia Research from November 1-4, 2022, in Dallas, Texas.

What is CTI-1601 being developed for?

CTI-1601 is being developed as a potential treatment for Friedreich's Ataxia.

Who is presenting the data on CTI-1601?

Nancy M. Ruiz, MD, the Chief Medical Officer of Larimar Therapeutics, will present the data.

What are some key topics of the presentations at the conference?

Key topics include safety, pharmacokinetics, and gene expression related to CTI-1601.